BiomX Inc
For the period ended Dec 31, 2023. Filed Apr 4, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 4, 2024
HLSQ$0.11-13.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | 14,907 | 31,332 |
| Restricted cash | 957 | 962 |
| Short-term deposits | - | 2,000 |
| Other current assets | 1,768 | 2,587 |
| Total current assets | 17,632 | 36,881 |
| Non-current assets | ||
| Operating lease right-of-use assets | 3,495 | 3,860 |
| Property and equipment, net | 3,902 | 4,790 |
| Total non-current assets | 7,397 | 8,650 |
| 25,029 | 45,531 | |
**CONSOLIDATED BALANCE SHEETS
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Trade account payables | 1,381 | 820 |
| Current portion of lease liabilities | 666 | 687 |
| Other account payables | 3,344 | 2,150 |
| Current portion of long-term debt | 5,785 | 4,282 |
| Total current liabilities | 11,176 | 7,939 |
| Non-current liabilities | ||
| Contract liability | 1,976 | 1,976 |
| Long-term debt, net of current portion | 5,402 | 10,591 |
| Operating lease liabilities, net of current portion | 3,239 | 3,798 |
| Other liabilities | 155 | 188 |
| Total non-current liabilities | 10,772 | 16,553 |
| Commitments and Contingencies (Note 10) | ||
| Stockholders’ equity | ||
| Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of December 31, 2023 and December 31, 2022. No shares issued and outstanding as of December 31, 2023 and December 31, 2022. | - | - |
| Common stock, $0.0001 par value (“Common Stock”); Authorized - 120,000,000 shares as of December 31, 2023 and December 31, 2022. Issued – 45,979,930 and 29,982,282 as of December 31, 2023 and 2022, respectively. Outstanding – 45,979,930 and 29,976,582 as of December 31, 2023 and 2022, respectively. | 3 | 2 |
| Additional paid in capital | 166,048 | 157,838 |
| Accumulated deficit | (162,970) | (136,801) |
| Total Stockholders’ equity | 3,081 | 21,039 |
| 25,029 | 45,531 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.